Navigation Links
Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
Date:8/3/2009

1-3 adverse events were vomiting, nausea, diarrhea, anorexia and abdominal pain.(7)

Updated efficacy and safety data from this study demonstrated that patients with an ECOG performance status of 0-1 had a median overall survival of 264 days (n=56).(7) These data suggest that BIBF 1120 has single-agent activity in patients suffering from recurrent NSCLC.(7) Preliminary data from this study were presented in April 2008 at the 1st European Lung Cancer Conference in Switzerland.

The data presented at WCLC, and the Phase III development of its two most advanced compounds, mark significant progress for Boehringer Ingelheim's evolving oncology pipeline. In addition to BIBW 2992 and BIBF 1120, Boehringer Ingelheim has several oncology compounds in earlier clinical and pre-clinical development.

Boehringer Ingelheim believes in evidence-based, scientific progress; its extensive oncology clinical trial program involves more than 800 study centers in 47 countries. Boehringer Ingelheim has a dedicated cancer research center in Vienna where scientists are focused on the discovery and development of new treatments to combat or alleviate the symptoms of cancer.

Clinical trial information

Additional information on the LUX-Lung 3 trial is available by calling the Boehringer Ingelheim toll-free number, 1-800-243-0127.

The global LUME-Lung Phase III clinical trial program is investigating BIBF 1120 in combination with standard second-line chemotherapy in patients with advanced NSCLC. The studies are ongoing with a recruitment target of 2,600 patients worldwide. This is one of the largest Phase III study programs in an advanced NSCLC patient population to date.(8,9)

About Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer.( )In 2008, approximately 1.52 million new cases of lu
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. AmeriCares and Boehringer Ingelheim Open New, Expanded Free Clinic to Help Families Hit Hardest by Economic Hardship
2. Boehringer Ingelheim Recognized For Diversity And Inclusion Efforts
3. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
4. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
5. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
6. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
7. Emdeon Inc. Commences U.S. Initial Public Offering of Class A Common Stock
8. Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan
9. HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Cogdell Spencer Announces Commencement of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- A group representing U.S. obstetricians is calling for ... According to the American College of Obstetricians and Gynecologists ... the safety and effectiveness of flu vaccination during pregnancy. ... be particularly dangerous to pregnant women, as it can ... Riley, chair of the college,s Immunization Expert Work Group, ...
(Date:8/20/2014)... discovered that the immune system is defective in people suffering ... sufferers have ongoing issues with pain. , The research ... also help to explain why some painkillers may not offer ... up to 10% of the community. There are different ... pain, which often has the greatest impact on sufferers, quality ...
(Date:8/20/2014)... Barbara Bronson Gray ... -- Although it,s extremely rare, colds, flu and other ... elevated risk for stroke in children, a new study suggests. ... a stroke in the United States, said Dr. Heather Fullerton, ... and pediatrics at the University of California, San Francisco Benioff ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... architecture firm Perkins Eastman is pleased to ... design services in China and the ... recognized Principal Richard Sprow AIA has relocated ... his 40-year career in healthcare planning and design and ...
(Date:8/20/2014)... August 20, 2014 With 3943.8% growth, Connexion ... of the nation’s fastest growing companies. The Inc. 500 ranks ... care sector. Connexion Point is the #1 fastest growing company ... Medicare and Medicaid, and its clients include four of the ... employs 1,000 people and has offices and contact centers in ...
Breaking Medicine News(10 mins):Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2
... Orchid Cellmark Inc. (Nasdaq: ORCH ), a leading ... financial results for the fourth quarter and full year of ... compared to $15.0 million for the fourth quarter of 2007. ... $60.3 million for the full year of 2007. The decline ...
... STXS ) today announced that it has extended its ... SVB Financial Group (Nasdaq: SIVB ). Under ... Company can borrow up to $25 million. "This extension ... position and other financing sources, provides us with the financial ...
... Meal Recipes, Educational Games and More Now Available SAN FRANCISCO, ... initiative to provide the public with information about how the ... brains healthy. In honor of Brain Awareness Week, which begins ... online that help people understand how the brain operates and ...
... HORSHAM, Pa. and TEL AVIV, Israel, March 16 ... of a strategic partnership agreement to provide a total, ... hemodynamic cardiovascular patient data to their customers. LUMEDX is ... more than 500 hospitals worldwide. With a presence ...
... Deerfield ManagementBEDFORD, Mass, March 16 Insulet Corporation ... tubing-free insulin pump technology with its OmniPod(R) Insulin ... into an agreement with leading healthcare investor, Deerfield ... $60 million in financing through a flexible credit ...
... both Raima Database Manager (RDM) products in April. ... and RDM Server will be released as version ... availability by providing replication between RDM Embedded databases ... of embedded systems with an easy method to ...
Cached Medicine News:Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:Stereotaxis Extends Its Credit Facility With Silicon Valley Bank 2Health News:Stereotaxis Extends Its Credit Facility With Silicon Valley Bank 3Health News:Posit Science Provides Free Brain Health Tips and Tools in Celebration of Brain Awareness Week 2Health News:LUMEDX and Mennen Medical(R) Announce Agreement for a Strategic Cooperation 2Health News:LUMEDX and Mennen Medical(R) Announce Agreement for a Strategic Cooperation 3Health News:Insulet Receives $60 Million Funding Commitment 2Health News:Insulet Receives $60 Million Funding Commitment 3Health News:Insulet Receives $60 Million Funding Commitment 4Health News:Insulet Receives $60 Million Funding Commitment 5Health News:Birdstep Technology Announces The Dual Upcoming Release Of Its Raima Database Manager Products 2Health News:Birdstep Technology Announces The Dual Upcoming Release Of Its Raima Database Manager Products 3
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
(Date:8/20/2014)... , August 20, 2014 ... report titled "Monochloroacetic Acid (MCA) Market for Cellulosics, Agrochemicals, ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... at USD 817.1 million in 2013 and is anticipated ... a CAGR of 3.6% during the forecast period from ...
(Date:8/20/2014)... -- Research and Markets has announced ... Care and Closure Market (Types, Applications, End User ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation ... their offering. The new report ... (types, applications, end user and geography) - Size, ...
Breaking Medicine Technology:Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
... indicates that anti-inflammatory drugs may become a new tool ... leading global cause of death. In investigating a specific ... researchers used the Cardiochip, a gene analysis tool designed ... Center for Applied Genomics at The Children,s Hospital of ...
... March 14, 2012 OncoSec Medical Incorporated ... Medical System (OMS) ElectroOncology therapies to treat solid ... Institute in Santa Monica, CA, and Lakeland Comprehensive ... as enrolling sites, and investigators are screening patients ...
Cached Medicine Technology:Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 2Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: